drugset / Trial / NCT02052349
Bioavailability of ABT-333 Within the Gastrointestinal Tract in Healthy Subjects
NaSingle-groupOpen-label
Summary
This open label, Phase 1 study is to investigate the relative bioavailability of ABT-333 when delivered within different sites of the gastrointestinal tract in 12 healthy subjects.
Timeline
- Start
- 2013-11
- Primary completion
- 2013-12
- Completion
- 2013-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | dasabuvir | Small molecule | — | — |
Indications
No indication recorded.